| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LILRB3 |
| Uniprot No | O75022 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-443aa |
| 氨基酸序列 | MTPALTALLC LGLSLGPRTR VQAGPFPKPT LWAEPGSVIS WGSPVTIWCQ GSQEAQEYRL HKEGSPEPL DRNNPLEPKN KARFSIPSMT EHHAGRYRCH YYSSAGWSEP SDPLEMVMTG AYSKPTLSA LPSPVVASGG NMTLRCGSQK GYHHFVLMKE GEHQLPRTLD SQQLHSRGFQ ALFPVGPVT PSHRWRFTCY YYYTNTPWVW SHPSDPLEIL PSGVSRKPSL LTLQGPVLAP GQSLTLQCG SDVGYNRFVL YKEGERDFLQ RPGQQPQAGL SQANFTLGPV SPSNGGQYRC YGAHNLSSE WSAPSDPLNI LMAGQIYDTV SLSAQPGPTV ASGENVTLLC QSWWQFDTFL LTKEGAAHP PLRLRSMYGA HKYQAEFPMS PVTSAHAGTY RCYGSYSSNP HLLSHPSEPL ELVVSGHSG GSSLPPTGPP STPGLGRYLE |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LILRB3重组蛋白的3篇参考文献示例(注：内容为模拟生成，非真实文献)：
---
1. **文献名称**：*Structural characterization of recombinant LILRB3 and its interaction with HLA class I molecules*
**作者**：Zhang Y, et al.
**摘要**：本研究通过X射线晶体学解析了重组LILRB3蛋白的胞外结构域，揭示了其与HLA-G的结合界面，为LILRB3在免疫耐受中的调控机制提供结构基础。
2. **文献名称**：*LILRB3 recombinant protein modulates macrophage polarization in tumor microenvironment*
**作者**：Liu X, et al.
**摘要**：实验证明，重组LILRB3蛋白可通过抑制SHP-1/STAT3通路，促进巨噬细胞向M2型极化，从而增强肿瘤免疫逃逸，提示其作为癌症治疗潜在靶点。
3. **文献名称**：*Recombinant LILRB3 inhibits inflammatory response in sepsis models via CD14/TLR4 pathway*
**作者**：Wang H, et al.
**摘要**：在脓毒症小鼠模型中，重组LILRB3蛋白通过阻断CD14与TLR4的相互作用，显著降低促炎因子(如TNF-α、IL-6)水平，缓解全身性炎症反应。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词**"LILRB3 recombinant protein"**，并筛选近五年内发表的实验性研究论文。
**Background of LILRB3 Recombinant Protein**
Leukocyte immunoglobulin-like receptor B3 (LILRB3), also known as ILT5 or CD85a, is a member of the LILR family of immune-regulatory receptors expressed primarily on myeloid cells, such as monocytes, macrophages, and dendritic cells. These receptors play critical roles in modulating immune responses by recognizing major histocompatibility complex (MHC) class I molecules and transmitting inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic domains. LILRB3. in particular, interacts with HLA-A, HLA-B, and HLA-G antigens, contributing to immune tolerance, suppression of inflammatory reactions, and prevention of autoimmune activation.
Structurally, LILRB3 is a transmembrane glycoprotein composed of extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail containing ITIMs. Its recombinant form is typically engineered using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, such as glycosylation, which are essential for ligand binding and functional activity. Recombinant LILRB3 proteins are purified via affinity chromatography, often fused with tags like Fc or His for detection and solubility enhancement.
Research on LILRB3 recombinant protein focuses on its dual role in immunity: dampening excessive immune activation in autoimmune diseases while potentially enabling immune evasion in cancers or chronic infections. Studies explore its therapeutic potential as a checkpoint inhibitor target or a tolerogenic agent in transplantation. Additionally, recombinant LILRB3 serves as a tool to study receptor-ligand interactions, signaling mechanisms, and crosstalk with other immune checkpoints like PD-1/PD-L1. Its applications extend to drug screening, structural biology, and biomarker discovery in diseases such as cancer, rheumatoid arthritis, and sepsis.
In summary, LILRB3 recombinant protein is a pivotal reagent for understanding immune modulation and developing therapies that fine-tune inhibitory pathways in health and disease.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
